{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:17:50Z","timestamp":1790396270979,"version":"4.1.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The immunomodulatory drug lenalidomide is used in patients with follicular lymphoma (FL) with the aim of stimulating T-cell antitumor immune response. However, little is known about the effects of lenalidomide on T-cell biology in vivo in patients with FL. We thus undertook an extensive longitudinal immunologic study, including phenotypic, transcriptomic, and functional analyses, on 44 first-line and 27 relapsed\/refractory patients enrolled in the GALEN trial (Obinutuzumab Combined With Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma) to test the efficacy of lenalidomide and obinutuzumab combination in patients with FL. Lenalidomide rapidly and transiently induced an activated T-cell phenotype, including HLA-DR, Tim-3, CD137, and programmed cell death protein 1 (PD-1) upregulation. Furthermore, sequential RNA-sequencing of sorted PD-1+ and PD-1\u2013 T-cell subsets revealed that lenalidomide triggered a strong enrichment for several gene signatures related to effector memory T-cell features, including proliferation, antigen receptor signaling, and immune synapse restoration; all were validated at the phenotypic level and with ex vivo functional assays. Correlative analyses pinpointed a negative clinical impact of high effector T-cell and regulatory T-cell percentages before and during treatment. Our findings bring new insight in lenalidomide mechanisms of action at work in vivo and will fuel a new rationale for the design of combination therapies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003774","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:09:58Z","timestamp":1618981798000},"page":"2063-2074","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2207-361X","authenticated-orcid":false,"given":"C\u00e9dric","family":"M\u00e9nard","sequence":"first","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rossille","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Dulong","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Tuan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Papa","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maelle","family":"Latour","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Bescher","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bezier","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Chouteau","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6437-4189","authenticated-orcid":false,"given":"Thierry","family":"Fest","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"Haematology Department, CHU Rennes, Rennes, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-917X","authenticated-orcid":false,"given":"Karin","family":"Tarte","sequence":"additional","affiliation":[{"name":"UMR 1236, Univ Rennes, INSERM, Etablissement Fran\u00e7ais du Sang Bretagne, Rennes, France;"},{"name":"SITI Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"issue":"4","key":"2021042015323251300_B1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2021042015323251300_B2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MOH.0000000000000440","article-title":"Microenvironment signaling driving lymphomagenesis","volume":"25","author":"Verdi\u00e8re","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"2021042015323251300_B3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","article-title":"Role of the microenvironment across histological subtypes of NHL","volume":"2017","author":"Tarte","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021042015323251300_B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","article-title":"The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity","volume":"24","author":"Am\u00e9-Thomas","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"2021042015323251300_B5","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"2021042015323251300_B6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2021042015323251300_B7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum Pathol"},{"issue":"2","key":"2021042015323251300_B8","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"2021042015323251300_B9","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.celrep.2019.01.085","article-title":"Mass cytometry analysis reveals that specific intratumoral CD4+ T cell subsets correlate with patient survival in follicular lymphoma","volume":"26","author":"Yang","year":"2019","journal-title":"Cell Rep"},{"issue":"8","key":"2021042015323251300_B10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"key":"2021042015323251300_B11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.humpath.2017.03.023","article-title":"Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients","volume":"64","author":"Xerri","year":"2017","journal-title":"Hum Pathol"},{"issue":"2","key":"2021042015323251300_B12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"issue":"31","key":"2021042015323251300_B13","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"28","key":"2021042015323251300_B14","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.18632\/oncotarget.24987","article-title":"MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma","volume":"9","author":"Malpeli","year":"2018","journal-title":"Oncotarget"},{"issue":"31","key":"2021042015323251300_B15","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"2021042015323251300_B16","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021042015323251300_B17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"2021042015323251300_B18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2021042015323251300_B19","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"2021042015323251300_B20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2021042015323251300_B21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2021042015323251300_B22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2021042015323251300_B23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"2021042015323251300_B24","doi-asserted-by":"crossref","first-page":"e1409322","DOI":"10.1080\/2162402X.2017.1409322","article-title":"NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment","volume":"7","author":"Vo","year":"2017","journal-title":"OncoImmunology"},{"issue":"25","key":"2021042015323251300_B25","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021042015323251300_B26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2021042015323251300_B27","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2021042015323251300_B28","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"14","key":"2021042015323251300_B29","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2018-05-853499","article-title":"An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed\/refractory follicular B-cell lymphoma","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2021042015323251300_B30","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2021042015323251300_B31","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2021042015323251300_B32","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"21","key":"2021042015323251300_B33","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"issue":"43","key":"2021042015323251300_B34","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2021042015323251300_B35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"18","key":"2021042015323251300_B36","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2021042015323251300_B37","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.4049\/jimmunol.1402550","article-title":"NF-\u03baB regulates PD-1 expression in macrophages","volume":"194","author":"Bally","year":"2015","journal-title":"J Immunol"},{"issue":"7","key":"2021042015323251300_B38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"2021042015323251300_B39","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-07-4797","article-title":"Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?","volume":"14","author":"M\u00e9nard","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2021042015323251300_B40","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4049\/jimmunol.1800570","article-title":"Activation of Th1 immunity within the tumor microenvironment is associated with clinical response to lenalidomide in chronic lymphocytic leukemia","volume":"201","author":"Aue","year":"2018","journal-title":"J Immunol"},{"issue":"1","key":"2021042015323251300_B41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev-immunol-032713-120236","article-title":"Metabolic regulation of immune responses","volume":"32","author":"Ganeshan","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"2021042015323251300_B42","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.3109\/10428194.2014.963578","article-title":"Clinicopathological characteristics of follicular lymphoma with peripheral blood involvement","volume":"56","author":"Maeshima","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2021042015323251300_B43","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12675","article-title":"Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis","volume":"164","author":"Sarkozy","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"2021042015323251300_B44","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00277-020-04208-x","article-title":"Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy","volume":"99","author":"Junl\u00e9n","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"2021042015323251300_B45","doi-asserted-by":"crossref","first-page":"13471","DOI":"10.1038\/s41598-019-50029-y","article-title":"Recovery of central memory and naive peripheral T cells in follicular lymphoma patients receiving rituximab-chemotherapy based regimen","volume":"9","author":"Milcent","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"2021042015323251300_B46","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"6871","key":"2021042015323251300_B47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"issue":"5","key":"2021042015323251300_B48","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2021042015323251300_B49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2021042015323251300_B50","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1111\/bjh.16876","article-title":"Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35\/10 trial","volume":"190","author":"Menter","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2021042015323251300_B51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/bjh.16414","article-title":"Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy","volume":"189","author":"Menter","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"2021042015323251300_B52","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.4049\/jimmunol.1201363","article-title":"Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment","volume":"190","author":"Rawal","year":"2013","journal-title":"J Immunol"},{"issue":"7","key":"2021042015323251300_B53","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"issue":"9","key":"2021042015323251300_B54","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/leu.2016.161","article-title":"Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells","volume":"30","author":"Pizzi","year":"2016","journal-title":"Leukemia"},{"issue":"74","key":"2021042015323251300_B55","doi-asserted-by":"crossref","first-page":"34009","DOI":"10.18632\/oncotarget.26131","article-title":"Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients","volume":"9","author":"Franssen","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"2021042015323251300_B56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/17474086.2015.998995","article-title":"Chemotherapy-free treatment in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2015","journal-title":"Expert Rev Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2063\/1805516\/advancesadv2020003774.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2063\/1805516\/advancesadv2020003774.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:10:36Z","timestamp":1618981836000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/8\/2063\/475736\/Lenalidomide-triggers-T-cell-effector-functions-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003774","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}